Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.

ABSTRACT:

Background

The recent mpox outbreak has disproportionately affected people with HIV (PWH) and resulted in the first widespread use of the novel antiviral tecovirimat. Whether treatment outcomes differ between PWH and those without HIV is unknown.

Objective

To compare the clinical presentation and treatment outcomes of PWH and HIV-negative persons with mpox virus (MPXV) infection treated with tecovirimat.

Design

Retrospective cohort study of patients treated with tecovirimat for confirmed MPXV infection from June to August 2022.

Setting

Two academic medical centers in New York City.

Participants

The study included 196 persons treated with tecovirimat from 20 June to 29 August 2022. Of 154 testing positive for MPXV, 72 were PWH and 4 had a CD4 count lower

SUBMITTER: McLean J 

PROVIDER: S-EPMC10344608 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature